4.7 Article

Parametric Methods for Quantification of 18F-FAZA Kinetics in Non-Small Cell Lung Cancer Patients

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 55, Issue 11, Pages 1772-1777

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.114.141846

Keywords

PET; hypoxia; non-small cell lung cancer; F-18-FAZA; parametric images

Funding

  1. Center for Translational Molecular Medicine (AIRFORCE project) [03O-103]

Ask authors/readers for more resources

F-18-fluoroazomycinarabinoside (F-18-FAZA) is a hypoxia-specific PET tracer. In future clinical applications of hypoxia imaging, such as early response monitoring or radiation therapy dose painting, accurate quantification of tracer uptake at the voxel level will be required. The aim of the present study was to assess the validity of parametric methods for the quantification of F-18-FAZA studies. Methods: Dynamic 70-min F-18-FAZA scans were obtained from 9 non-small cell lung cancer patients. Arterial blood samples, collected at 7 time points, were used for preprocessing an image-derived input function derived from volumes of interest (VOIs) defined within the ascending aorta. Time activity curves derived from various tumor VOIs were fitted using nonlinear regression analysis (NLR) to a reversible 2-tissue-compartment model, providing volumes of distribution (V-T) as an outcome measure. Next, parametric images were generated by use of both Logan graphic analysis with various linear regression start times and spectral analysis with multiple sets of basis functions. The previously defined tumor VOIs were projected onto these parametric images, and the resulting V-T were compared with those obtained from NLR. In addition, the results were compared with tumor-to-blood ratios (SUVr), which are more easily obtainable. Results: The highest correlations and correspondence with NLR-derived V-T were found for Logan graphic analysis with a start time of 30 min after injection (R-2, 0.88; intraclass correlation coefficient [ICC], (193) and for spectral analysis-derived V-T with a set of 30 basis functions with exponents ranging from 0.0175 to 1.9 (R-2, 0.79; ICC, 0.81). SUVr yielded similar correlations but showed significant bias at high V-T (R-2, 0.85; ICC, 0.80). Conclusion: Both Logan graphic analysis and spectral analysis yielded V-T that showed high correlations with nonlinear regression analysis-derived V-T. SUVr showed bias at high V-T.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma

M. J. E. Greuter, J. J. Eertink, G. Jongeneel, U. Duehrsen, A. Huettmann, C. Schmitz, P. J. Lugtenburg, S. F. Barrington, N. G. Mikhaeel, L. Ceriani, E. Zucca, R. Carr, T. Gyorke, C. N. Burggraaff, H. C. W. de Vet, O. S. Hoekstra, J. M. Zijlstra, V. M. H. Coupe

Summary: Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting towards shorter treatment duration, but it is unclear whether shortening treatment duration causes harm. Using a Markov model, this study evaluated the cost-effectiveness of shortening treatment duration based on I-PET results, showing that it is justified to shorten treatment duration for I-PET negative patients but not for I-PET positive patients as it has harmful consequences.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Article Biochemistry & Molecular Biology

Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients

Sander Bach, Birgit M. M. Wever, Mark A. van de Wiel, Joris D. Veltman, Sayed M. S. Hashemi, Geert Kazemier, Idris Bahce, Renske D. M. Steenbergen

Summary: This study investigated the circadian variation of urinary cfDNA abundance and methylation levels of cancer-associated genes in NSCLC patients. It found that men had significantly lower cfDNA concentrations and the variability in cfDNA levels between and within subjects was comparable with an ICC of 0.49. The study also found that the reproducibility of methylation markers varied considerably, ranging from 0.14 to 0.74, emphasizing the importance of collecting multiple samples per patient to improve test reproducibility.

EPIGENETICS (2022)

Review Immunology

Folate Receptor Beta for Macrophage Imaging in Rheumatoid Arthritis

Maarten M. Steinz, Aiarpi Ezdoglian, Fatemeh Khodadust, Carla F. M. Molthoff, Madduri Srinivasarao, Philip S. Low, Gerben J. C. Zwezerijnen, Maqsood Yaqub, Wissam Beaino, Albert D. Windhorst, Sander W. Tas, Gerrit Jansen, Conny J. van der Laken

Summary: Non-invasive imaging modalities, particularly macrophage imaging with folate-based PET tracers, hold great promise in diagnostic and therapy response monitoring of autoimmune diseases.

FRONTIERS IN IMMUNOLOGY (2022)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner

Adrienne H. Brouwers, Joyce van Sluis, Johannes H. van Snick, Carolina P. Schroder, Inge O. Baas, Ronald Boellaard, Andor W. J. M. Glaudemans, Ronald J. H. Borra, Adriaan A. Lammertsma, Rudi A. J. O. Dierckx, Charalampos Tsoumpas

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Review Oncology

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Wietske I. Luining, Matthijs C. F. Cysouw, Dennie Meijer, N. Harry Hendrikse, Ronald Boellaard, Andre N. Vis, Daniela E. Oprea-Lager

Summary: Imaging plays a crucial role in the accurate staging of prostate cancer, and targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value. PSMA-based imaging techniques have shown superior detection rates compared to previous methods, and PSMA has also become a target for delivering radionuclide therapy. This review summarizes recent developments in nuclear medicine related to PSMA in prostate cancer diagnostics and targeted radionuclide therapy, highlighting the potential benefits of PSMA-positron emission tomography (PET) imaging and PSMA-based radioligand therapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

CANCERS (2022)

Article Oncology

Ontario, Canada. 7

Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries

Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.

CLINICAL CANCER RESEARCH (2023)

Article Endocrinology & Metabolism

Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals

Fiona Heeman, Denise Visser, Maqsood Yaqub, Sander Verfaillie, Tessa Timmers, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, Bart N. M. van Berckel, Ronald Boellaard, Adriaan A. Lammertsma, Sandeep S. Golla

Summary: Alzheimer's disease is characterized by reduced cerebral blood flow. This study compared the precision of different methods for measuring cerebral blood flow and found that relative blood flow methods had better repeatability than absolute blood flow methods. The high precision of relative blood flow may be due to a compensatory effect of the extraction fraction.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification

Anne M. Smith, Nancy A. Obuchowski, Norman L. Foster, Gregory Klein, P. David Mozley, Adriaan A. Lammertsma, Richard L. Wahl, John J. Sunderland, Jean-Luc Vanderheyden, Tammie L. S. Benzinger, Paul E. Kinahan, Dean F. Wong, Eric S. Perlman, Satoshi Minoshima, Dawn Matthews

Summary: Standardized approach in acquiring amyloid PET images increases their value as disease and drug response biomarkers. The Quantitative Imaging Biomarkers Alliance amyloid PET biomarker committee developed and validated a profile to characterize and reduce the variability of SUVRs, increasing statistical power for these assessments.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

[18F]Fluoride PET provides distinct information on disease activity in ankylosing spondylitis as compared to MRI and conventional radiography

Jerney de Jongh, Nicki J. F. Verweij, Maqsood Yaqub, Christiaan J. van Denderen, Irene E. van der Horst-bruinsma, Joost C. J. Bot, Bouke J. H. Boden, Robert Hemke, Frank F. Smithuis, Willem F. Lems, Adriaan A. Lammertsma, Alexandre E. Voskuyl, Maarten Boers, Gerben J. C. Zwezerijnen, Conny J. van der Laken

Summary: Lesions detected on [F-18]fluoride PET scans often fall outside the scope of MRI and CR, with partial overlap with abnormalities seen on MRI (especially BME) and CR (especially ankylosis). PET activity shows the strongest association with BME on MRI and ankylosis on CR.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Article Oncology

Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC

Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, Lynette M. Sholl, Weiwei Shi, Joao Alessi, Alessio Cortellini, Claudia A. M. Fulgenzi, Patrizia Viola, David J. Pinato, Sayed Hashemi, Idris Bahce, Ilias Houda, Ezgi B. Ulas, Teodora Radonic, Juha P. Vayrynen, Elin Richardsen, Simin Jamaly, Sigve Andersen, Tom Donnem, Mark M. Awad, David J. Kwiatkowski

Summary: This study developed a machine-learning-based approach to evaluate the association between tumor-infiltrating lymphocytes (TILs) and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. The results showed that high levels of TILs were associated with ICI treatment response and could be used for patient selection and precision therapy guidance.

JAMA ONCOLOGY (2023)

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer

Wyanne A. Noortman, Nicolas Aide, Dennis Vriens, Lisa S. Arkes, Cornelis H. Slump, Ronald Boellaard, Jelle J. Goeman, Christophe M. Deroose, Jean-Pascal Machiels, Lisa F. Licitra, Renaud Lhommel, Alessandra Alessi, Erwin Woff, Karolien Goffin, Christophe Le Tourneau, Jocelyn Gal, Stephane Temam, Jean-Pierre Delord, Floris H. P. van Velden, Lioe-Fee de Geus-Oei

Summary: The study aimed to build and externally validate an [F-18]FDG PET radiomic model for predicting overall survival in patients with head and neck squamous cell carcinoma. Two multicentre datasets were used to train and validate the model, which included patients treated with preoperative afatinib. The radiomic model outperformed the clinical model in predicting overall survival.

CANCERS (2023)

Article Oncology

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne

Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu

Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Oncology

Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology

Mostafa Roya, Samaneh Mostafapour, Philipp Mohr, Laura Providencia, Zekai Li, Johannes H. van Snick, Adrienne H. Brouwers, Walter Noordzij, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Andor W. J. M. Glaudemans, Charalampos Tsoumpas, Riemer H. J. A. Slart, Joyce van Sluis

Summary: Recently, a new type of PET scanner with long axial field-of-view (LAFOV) has been introduced in clinical practice. Compared to conventional PET scanners, LAFOV scanners have a larger coverage and higher sensitivity, providing new opportunities for clinical applications, such as reducing scan time, decreasing the amount of radiotracer used, and using dynamic or parametric imaging. Emerging technologies like artificial intelligence and imaging with multiple radiotracers can further enhance the clinical application of LAFOV PET.

CANCERS (2023)

No Data Available